EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieVergleichsstudie

The use of letrozole or mifepristone for pre‐treatment of medical termination of pregnancy: A randomized, non‐inferiority trial

Aimee Chuin Ai Teong iD, Tiffany Tuck Chin Wong, Ni Ni Soe, Hester Chang Qi Lau, Cassandra Yang Xuan Ang, See Ling Loy, Chee Wai Ku, Jerry Kok Yen Chan, Shahul Hameed Mohamed Siraj, Manisha Mathur, Meei Jiun Seet

International Journal of Gynecology & Obstetrics · 2026-12 · 175 (3) · 1287-1295

DOI: 10.1002/ijgo.71104 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 16.06.2026. Verfasst von Aimee Chuin Ai Teong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore. Hauptthemen laut MEDLINE: Letrozole, Mifepristone, Abortion, Induced, Abortifacient Agents, Steroidal. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Duke-NUS Medical School.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Mifepristone improves the effectiveness of medical termination of pregnancy (mTOP) but is expensive and restricted in some settings. Letrozole has been proposed as a potential alternative. This study aimed to evaluate whether letrozole is non‐inferior to mifepristone as a pre‐treatment for mTOP.

Methods

We conducted an assessor‐blinded, randomized controlled non‐inferiority trial comparing mifepristone versus letrozole pre‐treatment for mTOP. Participants were randomized to one of two groups: the control group received oral mifepristone 200 mg on Day 1, while the intervention group received oral letrozole 10 mg daily from Day 1 to Day 3. On Day 3, both groups received per‐vaginal misoprostol 800 mcg, followed by an additional 400 mcg after 4 h if there were no signs of abortion. Follow‐up was conducted by Day 28 post‐mTOP. The primary outcome was complete abortion, defined as a negative urine pregnancy test with no ongoing vaginal bleeding and no need for surgical evacuation by Day 28. Data was analyzed using SPSS Version 30.0.

Results

The intention‐to‐treat analysis included 135 participants, with a mean gestational age of 8.2 weeks. Complete abortion occurred in 72.1% (49/68) of the letrozole group compared with 85.1% (57/67) of the mifepristone group, with an absolute risk difference of −13.0% (95% CI −26.4 to +0.9). The lower bound of the 95% CI crossed the prespecified non‐inferiority margin of −15%, so non‐inferiority was not demonstrated.

Conclusion

Letrozole could not be shown to be a non‐inferior alternative to mifepristone as pre‐treatment for mTOP. Trial Registration This study was registered with ClinicalTrials.gov (ID: NCT05341817) on April 5, 2022, and received ethics board approval from the SingHealth Centralized Institutional Review Board (CIRB 202110–00035).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LetrozoleMifepristoneAbortion, InducedAbortifacient Agents, SteroidalHumansFemalePregnancyAdultMisoprostolAdministration, OralYoung AdultTreatment Outcome

Stichwörter der Autor:innen

induced abortionletrozolemifepristonemisoprostolpregnancy first trimesterrandomized controlled trial

Substanzen

LetrozoleMifepristoneMisoprostolAbortifacient Agents, Steroidal

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore.
  • Department of Reproductive Medicine, KK Women's and Children's Hospital, Singapore.
  • Duke-NUS Medical School, Singapore.
  • Maternal and Child Health Research Institute, KK Women's and Children's Hospital, Singapore.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Minimally Invasive Surgery Unit, KK Women's and Children's Hospital, Singapore.

ORCID-Profile: Aimee Chuin Ai Teong

Förderung

  • Duke-NUS Medical School

Zitieren

APA

Teong, A. C. A., Wong, T. T. C., Soe, N. N., Lau, H. C. Q., Ang, C. Y. X., Loy, S. L., Ku, C. W., Chan, J. K. Y., Mohamed Siraj, S. H., Mathur, M., & Seet, M. J. (2026). The use of letrozole or mifepristone for pre‐treatment of medical termination of pregnancy: A randomized, non‐inferiority trial. International Journal of Gynecology & Obstetrics, 175(3), 1287-1295. https://doi.org/10.1002/ijgo.71104

Vancouver

Teong ACA, Wong TTC, Soe NN, Lau HCQ, Ang CYX, Loy SL, et al. The use of letrozole or mifepristone for pre‐treatment of medical termination of pregnancy: A randomized, non‐inferiority trial. International Journal of Gynecology & Obstetrics. 2026;175(3):1287-1295. doi:10.1002/ijgo.71104

BibTeX
@article{Teong2026,
  author = {Teong, Aimee Chuin Ai and Wong, Tiffany Tuck Chin and Soe, Ni Ni and Lau, Hester Chang Qi and Ang, Cassandra Yang Xuan and Loy, See Ling and Ku, Chee Wai and Chan, Jerry Kok Yen and Mohamed Siraj, Shahul Hameed and Mathur, Manisha and Seet, Meei Jiun},
  title = {The use of letrozole or mifepristone for pre‐treatment of medical termination of pregnancy: A randomized, non‐inferiority trial},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2026},
  volume = {175},
  number = {3},
  pages = {1287--1295},
  doi = {10.1002/ijgo.71104}
}
Kostenlos starten →